Huaren Pharmaceutical announced that its wholly-owned subsidiary, Anhui Hengxing Pharmaceutical Co., Ltd., recently received the Approval Notice for the Listing Application of Yinxin Alkaloid Hydrochloride API issued by the National Medical Products Administration. Yinxin Alkaloid Hydrochloride is used to treat ischemia caused by spasm of the brain, heart, and peripheral blood vessels, and visceral spasms of the kidney, gallbladder, or gastrointestinal tract.
华仁药业：盐酸罂粟碱获上市申请批准通知书
Huaren Pharmaceutical: Yinxin alkaloid hydrochloride receives notification of application for listing approval
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.